Global Leader in Biotech BIOCAD is a leading biotechnology company in Russia with a strong focus on innovative drug development for complex health conditions like cancer, HIV, and Hepatitis C infections. Its world-class R&D center and manufacturing facilities position it as a key player in the pharmaceutical industry globally.

Diversified Product Portfolio With a dedication to developing medicines for a wide range of health disorders, including multiple sclerosis, BIOCAD offers a diversified product portfolio. This variety of treatment options creates opportunities for partnerships and collaborations in different therapeutic areas.

Advanced Technology Integration BIOCAD utilizes advanced technologies such as React, Yandex.Metrika, and Google Tag Manager, showcasing a commitment to innovation in drug development and marketing. Leveraging cutting-edge tech tools can attract tech-savvy partners and investors looking to collaborate on novel projects.

COVID-19 Response Amid the COVID-19 pandemic, BIOCAD's development of an mRNA vaccine against SARS-CoV-2 demonstrates its agility and capability to respond to global health crises. This initiative positions the company as a key player in the fight against COVID-19 and opens doors for partnerships in vaccine development.

Expansion into Clinical Research The recent launch of a clinical research information platform by BIOCAD indicates a strategic move towards enhancing its research capabilities. This expansion creates opportunities for collaboration with research institutions, CROs, and healthcare organizations interested in leveraging advanced clinical research tools.